HP518 e sibollotsoe le ho ntlafatsoa ke sethala sa Hinova sa ho sibolla lithethefatsi tse senyang protheine. E na le monyetla oa ho hlola khanyetso ea lithethefatsi ea mofetše oa senya ka lebaka la liphetoho tse itseng tsa AR.
Li-degraders tsa Chimeric ke limolek'hule tse nyenyane tse sebetsang habeli tse khothalletsang ho senyeha ha liprotheine tse lebisitsoeng tse nang le matla a phahameng le khetho e phahameng. Theknoloji ena e na le monyetla oa ho shebana le lipheo tse sa sebeliseng lithethefatsi le ho hlola taba ea khanyetso ea lithethefatsi ea litlhare tse tloaelehileng tsa molek'hule.
"Ena ke ketsahalo ea bohlokoa tsoelo-peleng ea boiteko ba rona ho tloha ho sibollo ea lithethefatsi ho fihlela thutong ea bongaka," ho boletse Yuanwei Chen, Ph.D., Mopresidente le CEO oa Hinova. "Re thabile ka hona 'me re ikemiselitse ho tlisa mekhoa e mecha ea phekolo ho bakuli lefatšeng ka bophara!"
Ka sethala se reriloeng sa ho sibolla lithethefatsi tsa protheine, Hinova e khona ho shebisisa ts'ebetso ea pholiso ea protheine kapele mme e fihlelle moralo o nepahetseng le ntlafatso ea li-chimeric degraders. Ho feta moo, Hinova o na le phihlelo e tebileng ea ho laola lik'hemik'hale tsa lik'hemik'hale tsa Chimeric degrader compounds.
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- Through the targeted protein degradation drug discovery platform, Hinova can screen protein degradation activity rapidly and accomplish efficient design and optimization of chimeric degraders.
- “This is a significant milestone in the progress of our efforts from drug discovery to the clinical study,”.
- This technology has the potential to target non-druggable targets and to overcome the drug resistance issue of traditional small molecule drugs.
